1. 2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial. (September 2015) Authors: Laquente, B.; Conill, C.; Fabregat, J.; Cambray, M.; Ayuso, J.R.; Valls, C.; Bombí, J.A.; Serrano, T.; Ferrández, A.; Povés, I.; Sabater, L.; Montagut, C.; Roselló, S.; Martín-Richard, M.; Díaz-Beveridge, R.; Rodriguez, J.; Gallego, R.; García-Alb éniz, X.; Fernández-Cruz, L.; Maurel, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study. (19th October 2016) Authors: Brisset, A. C.; Ferrández, A.; Krause, M.; Rathbun, S.; Marlar, R.; Korte, W. Journal: Journal of thrombosis and haemostasis Issue: Volume 14:Number 11(2016:Nov.) Page Start: 2187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗